SpikImm Announces the Signature of an Exclusive License Option and Collaboration Agreement With SATT Conectus for the Development of a Prophylactic Treatment Against the BK Virus, Causing Severe Complications in Transplant Patients

Contributed by: Business Wire

Tags

COVID-19
Research
Infectious Diseases
Clinical Trials
Biotechnology
Other Health
Health
Other Science
Science
SATT Conectus

More Like This

Ultrastructural representation of the BK polyomavirus capsid, featuring 72 pentamers that form its distinct icosahedral symmetry. (Graphic: Business Wire)

Orthogon Therapeutics Closes Oversubscribed $5.2M Financing to Advance First Oral Therapy for BK Polyomavirus

HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data

PR Newswire associated0

VST BIO Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Monoclonal Antibody to Treat Ischemic Stroke at AHA International Stroke Conference

Intravacc announces publication of In Vitro alternative to replace animal pyrogen test for vaccines

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma

Business Wire logo

ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV

PR Newswire associated0

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections